Abstract: Introduction: Ovulation dysfunction is one of the most common causes (prevalence 30-40%) of infertility. PCOS is one of the common cause of infertility. Letrozole is a potent, non stetoidal, aromatase inhibitor which is currently being used as ovulation inducing agent with few side effects. The aim is use of Letrozole as a first line ovulation inducing agent in polycystic ovarian syndrome (PCOS) as an alternative other commonly used ovulation induction agent.
Methods: Total 220 patients of PCOS were included in the study. Diagnosis of PCOS was made on Rotterdam criteria. All patients received 2.5 mg Letrozole daily since day 2-6 of cycle. Human chorionic gonadotrophin was administered at a dose of 5,000 IU when at least 1 mature follicle (17-25mm) was detected. Timed intercourse was advised to the patients after 24-36 hrs of hCG. Then the number of follicles, endometrial thickness, ovulation rate & pregnancy rate were measured.
Results: In this study 95.45% patients ovulated on first cycle, mono follicular development was significant greater in majority (86.4%) and only 2 patients developed mild OHSS, with good endometrial response, majority developed ET > 7.1mm. Out of 220 patients, 42 patients conceived out of which 14 had miscarriage, 10 had ectopic pregnancy.
Conclusion: Letrozole can be used as a first line drug to induce ovulation and pregnancy in PCOS patients.
Indexed in Index Copernicus
